Negative impactCompany
Moderna has been on a tear since mid-August. Citi now sees it plunging 60%
CNBC-TV18 54 min ago·1 Oct 2026, 12:54 am
Shares of biotech giant Moderna have surged significantly since mid-August, driven by optimism surrounding its vaccine pipeline. However, that momentum has hit a roadblock. Citi analyst Geoff Meacham has downgraded the stock to a 'sell' rating, citing concerns over the company's valuation and future growth prospects.
This downgrade is significant for investors as it signals a shift in institutional sentiment. A 'sell' rating implies that the analyst believes the stock is overvalued relative to its current performance and potential risks. It serves as a warning to retail investors to proceed with caution and reassess their risk tolerance before making any new investment decisions.
Investors should keep a close watch on Moderna's upcoming clinical trial results and its guidance for the coming quarters. These factors will be crucial in determining whether the stock can sustain its recent gains or if the recent pullback is the beginning of a longer-term correction.
Key takeaways
- Category: Company.
- AI reads the tone as negative (potentially bearish) for the stock.
Why it matters
A routine update. The tone is negative — watch for downside reaction. Use the price and stock snapshot to gauge how the market is responding.
